Form 8-K - Current report:
SEC Accession No. 0001564590-20-037260
Filing Date
2020-08-06
Accepted
2020-08-06 07:45:30
Documents
17
Period of Report
2020-08-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ntla-8k_20200806.htm   iXBRL 8-K 42006
2 EX-99.1 ntla-ex991_6.htm EX-99.1 63054
3 GRAPHIC gegtvn55xvrg000002.jpg GRAPHIC 1994
4 GRAPHIC gegtvn55xvrg000001.jpg GRAPHIC 5168
5 GRAPHIC gegtvn55xvrg000008.jpg GRAPHIC 51161
6 GRAPHIC gegtvn55xvrg000009.jpg GRAPHIC 21094
  Complete submission text file 0001564590-20-037260.txt   356033

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA ntla-20200806.xsd EX-101.SCH 5768
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE ntla-20200806_lab.xml EX-101.LAB 19475
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ntla-20200806_pre.xml EX-101.PRE 11626
10 EXTRACTED XBRL INSTANCE DOCUMENT ntla-8k_20200806_htm.xml XML 3550
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37766 | Film No.: 201079870
SIC: 2835 In Vitro & In Vivo Diagnostic Substances